Clinical trials: IL6
Obstructive Sleep Apnea
A Pilot Study of Biomarkers in Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is common and is a risk factor for postoperative complications, including respiratory and cardiac events and delirium.
- Trial name
- Cytokine OSA (NCT02325687)
- Testing
- Lumbar Puncture (Standard-of-Care)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Hospital for Special Surgery, New York
Squamous Cell Carcinoma Of The Head And Neck
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached…
- Trial name
- NCT01488318
- Testing
- Cetuximab, Dasatinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Julie E. Bauman, MD, MPH
Congenital Heart Disease
Washed Versus Standard Blood Cell Transfusions in Pediatric Open Heart Surgery
Background: Children having open heart surgery to repair congenital heart defects demonstrate a large inflammatory response to the heart-lung machine and to surgery itself.
- Trial name
- NCT00693498
- Testing
- Standard leukoreduced irradiated blood cell transfusion, Washed leukoreduced irradiated blood cell transfusions
- Volunteers
- 162 people
- Sponsor
- University of Rochester
Myeloma
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
The goal of this clinical research study is to find the highest tolerable dose of Siltuximab that can be given in combination with Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone to patients with MM.
- Trial name
- NCT01531998
- Testing
- Lenalidomide, Bortezomib, Siltuximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
COVID-19
Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
In this study, the investigators propose to administer clazakizumab to patients with life-threatening Coronavirus Disease 2019 (COVID-19) infection manifest by pulmonary failure and a clinical picture consistent with a cytokine…
- Trial name
- NCT04381052
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University